Biologics In Focus
Welcome to the August edition of “Biologics In Focus”, Lonza’s monthly newsletter dedicated to the biologics industry.
Each month, we provide in-depth analysis of industry trends, expert insights, event previews, and the latest Lonza news, along with real-customer stories. If you enjoy reading this month's edition, why not subscribe to ensure you never miss an update?
Lonza News and Updates
Discover how Lonza's mRNA research services are advancing the future of biologics. This article explores how Lonza’s expertise can help overcome challenges in mRNA research and drive innovation in therapeutic development.
Insights and Analysis
Explore effective technology transfer strategies, designed to optimize your clinical and commercial biologics supply. Learn best practices for seamless knowledge transfer, minimizing risks and ensuring successful production scale-up. Whether you're navigating early-stage development or expanding commercial operations, Lonza's expert insights can help streamline processes and enhance the success of your biologics programs.
Delve into Lonza's GS Xceed? expression system, a key technology driving the development of antibody-based immunotherapies. Learn how Lonza's advanced solutions enhance cell line development, boost productivity and accelerate time-to-market for therapeutic antibodies. Discover the role of innovative tools and expertise in advancing the next generation of immunotherapies for challenging diseases.
Discover how biopharmaceutical companies are addressing the challenge of global access to essential medications. This article examines key approaches, including collaboration with global health organizations, scaling up local production, and implementing equitable pricing strategies. Learn how these efforts aim to reduce healthcare inequality and make critical treatments more accessible to those in need around the world.
Lonza in the Press
Analytical advancements are revolutionizing mRNA research by enhancing methods for assessing mRNA quality and efficacy. This piece delves into the sophisticated techniques that ensure the reliability and success of mRNA-based therapies. Showcasing these innovations highlights their crucial role in advancing mRNA technology and expediting the development of cutting-edge treatments.
A surge in biomanufacturing facility construction is being driven by increased outsourcing in the U.S. pharmaceutical industry. Drugmakers are capitalizing on this trend to expand production capabilities and meet growing demand. The piece examines the factors fueling this boom and the implications for the biomanufacturing sector's future, emphasizing evolving industry dynamics.
In this Q&A, Lonza experts share their expertise on accelerating development timelines, integrating new technologies, navigating regulatory hurdles, and ensuring high-quality standards. Read more to discover how Lonza’s inventive approaches and cross-functional teamwork enhance critical therapeutics process development.
Customer Case Study
Explore how William B. Jones, Ph.D., CEO of Corvus Pharmaceuticals, leveraged a strategic partnership with Lonza to advance Corvus Pharmaceuticals’ therapeutic antibody. Lonza’s tailored solutions and expertise played a crucial role in overcoming challenges and accelerating the development of their molecule to the clinic.
Key Upcoming Events
Upcoming Webinars
Monday, September 30. 11am ET | 5pm CET Register here
Innovative Solutions for Enhancing Biotherapeutic Expression and Development
Thank you for reading. Remember to subscribe so you never miss our monthly updates.
If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.